canSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
- Bild-Infos
- Download
2 Dokumente
- canSERV_Challenge Ca~er Patient Care.pdf
PDF - 186 kB - canSERV_Challenge Ca~g of Cancer (2).pdf
PDF - 142 kB
REMINDER
Free Access to Cutting-Edge Research Services and Training:
Apply for canSERV Funding Opportunities this Summer to Accelerate Your Cancer Research
To advance the understanding of cancer and accelerate ground-breaking discoveries and their translation into clinical applications, the canSERV consortium invites cancer researchers world-wide to apply for free access to cutting-edge transnational research services and training. Two Challenge-driven Calls are open for researchers to apply for.
In line with the EU Cancer Mission, canSERV aims to improve the comprehension of cancer and innovative cancer therapies. To achieve this, the consortium of 18 leading research organisations offers free-of-charge access to 400+ state-of-the-art research services. These services can be requested for excellent research questions via the canSERV project website and the unique Common Access Management System. They are provided by 13 European life science research infrastructures and associated service providers in the following fields:
- Disease models
- Advanced technologies for personalised oncology
- Biomarkers research, development and validation
- New therapeutic solutions
- Accelerated translation into personalised oncology clinical practice
- Open digital research services
- Access to human samples and data
- Clinical trials and design
- Ethical, legal and socio-economic dimensions
- Training
A detailed service list is available in the canSERV Service Catalogue.
Currently, the consortium invites applications to the following two Challenge-driven Calls. For both Calls, a minimum of two services from the canSERV Service Catalogue should be requested. Training is considered as separate additional services.
1. REACHING AN UNDERSTANDING OF CANCER
A budget of 750.000€ has been reserved for research projects to advance the understanding of cancer. Projects submitted in response to this call may include, but are not limited to:
- Addressing cancer with poor prognosis
- Cancers with rising incidence
- Cancer and inflammation
- Identification of new modifiable cancer risk factors
- Identification of targets to develop biomarkers for prevention, early detection, personalised treatment and monitoring of minimal residual disease or relapse.
Submission closes on 23 July, at 14.00 CEST.
2. REVOLUTIONISING CANCER PATIENT CARE
A budget of 600.000€ has been allocated for “Revolutionising Cancer Patient Care: Innovative Approaches to Research and Clinical Trials for Improved Treatment Outcomes”.
Projects submitted in response to this call should focus on one of two topics:
- Tailoring research to address the different age groups, paediatric patients, and elderly patients, to ensure optimal treatment outcomes across diverse populations.
- Designing and developing improved clinical trials to address diverse populations and expand the scope to incorporate broader representation of patients from EU, including efforts to match control groups, thus advancing trial efficiency and equity in treatment access. Please note that canSERV does not fund clinical trials themselves; instead, users can apply for expert advice and support for planning and designing complex clinical trials.
Submission closes on 28 August, at 14.00 CEST.
Both calls are aimed at researchers based in European and non-European countries, including junior and senior individual researchers, academic institutes, biotech/pharmaceutical SMEs, groups of scientists, networks and consortia from public and private entities.
Applications will be reviewed by an international, independent, expert review panel.
Further information:
canSERV website: www.canserv.eu
Twitter: @canSERV_EU
LinkedIn: canSERV
Project coordination, BBMRI-ERIC:
Prof. Jens K. Habermann, Director General
Judit Balogh, Senior project manager
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101058620.
The information and views set out in this press release are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein.
ARTTIC Innovation GmbH has been advising research and innovation projects for more than 33 years. As project management and communication partner, we make sure that our projects run successfully and that project results and events are disseminated in the best possible way. ARTTIC is a subsidiary of the PNO Group, one of the largest consultancies for publicly funded projects in research and development. For more information, please visit www.arttic-innovation.de.
We take your privacy seriously. Click here to read our privacy policy. If you no longer wish to receive emails from us, please click below.